ImmunoCellular Therapeutics, Ltd.
(NYSE Amex Equities : IMUC)

( )
IMUC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.10%176.471.2%$601.40m
GILDGilead Sciences, Inc.
-0.57%67.630.9%$539.35m
BIIBBiogen Inc.
-0.97%277.671.2%$514.24m
CELGCelgene Corporation
-4.70%74.691.2%$489.59m
REGNRegeneron Pharmaceuticals, Inc.
-1.73%296.602.6%$311.33m
ALXNAlexion Pharmaceuticals, Inc.
-1.40%119.372.0%$249.70m
ILMNIllumina, Inc.
-0.51%268.293.5%$243.07m
VRTXVertex Pharmaceuticals Incorporated
-0.65%156.221.9%$235.00m
NKTRNektar Therapeutics
-2.15%83.476.0%$207.63m
AAgilent Technologies, Inc.
1.91%65.551.5%$202.86m
INCYIncyte Corporation
-1.53%66.792.5%$191.53m
SRPTSarepta Therapeutics, Inc.
-2.84%90.8316.6%$127.57m
EXASExact Sciences Corporation
-0.13%52.2925.5%$115.91m
BMRNBioMarin Pharmaceutical Inc.
0.54%89.364.4%$115.05m
ALNYAlnylam Pharmaceuticals, Inc
-1.96%100.809.8%$101.63m

Company Profile

ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.